10-K: NovAccess Global Inc. Files 10-K, Reports on Immunotherapy Development and Financial Status

NovAccess Global Inc.'s 10-K filing details its focus on developing novel immunotherapies for brain tumors, its financial challenges, and a recent significant funding agreement.

Summary

• NovAccess Global Inc., a biopharmaceutical company, is focused on developing immunotherapies for brain tumors, particularly glioblastoma.
• The company is preparing to file an Investigational New Drug Application (IND) with the FDA to begin human clinical trials for its lead drug candidate, TLR-AD1, in 2024.
• NovAccess received orphan drug designation for TLR-AD1 from the FDA in October 2022, which provides benefits such as marketing exclusivity and tax credits.
• The company has a history of losses and a working capital deficit of $7,798,484 as of September 30, 2023.
• A recent securities purchase agreement with Sumner Global LLC is expected to provide $3.63 million in equity and $7.05 million in loans, subject to certain conditions.
• The company's net loss for fiscal year 2023 was $4,724,946, compared to a net loss of $1,715,959 in fiscal year 2022.
• NovAccess has outstanding debt of approximately $2.2 million, some of which is in default, and requires at least $5.0 million through December 31, 2024, to continue operations.
• The company relies on third-party contract manufacturers for its vaccine products and faces risks related to manufacturing capacity and supply disruptions.
• NovAccess is a smaller reporting company with limited staff and assets, and its stock trades on the OTCQB with limited and sporadic trading.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive aspects such as the novel technology and orphan drug designation, the significant financial challenges, including a going concern opinion and substantial debt, create a negative sentiment from an investment perspective. The reliance on a single technology and the uncertainty of clinical trial outcomes further contribute to the low score.

Positives

• The company has a lead drug candidate, TLR-AD1, with a novel approach to treating brain cancer using the patient's own immune system.
• The FDA has granted orphan drug designation for TLR-AD1, which provides potential benefits.
• The company has a planned capital injection of $3.63 million in equity and $7.05 million in loans from Sumner Global LLC.
• NovAccess has a scientific advisory board with expertise in immunology, stem cell biology, and neuroscience.
• The company has an exclusive patent license from Cedars-Sinai Medical Center for its TLR-AD1 technology.

Negatives

• The company has a history of losses and a significant working capital deficit.
• NovAccess has outstanding debt of approximately $2.2 million, some of which is in default.
• The company has a going concern audit opinion, indicating substantial doubt about its ability to continue as a going concern.
• The company is dependent on the success of its TLR-AD1 platform technology, with other technologies in pre-clinical development.
• The company has limited experience in conducting and managing clinical trials.
• The company relies on third-party contract manufacturers and may face issues with manufacturing agreements, capacity limitations, and supply disruptions.
• The company's stock trades on the OTCQB with limited and sporadic trading.

Risks

• The company may not be able to complete the financing transaction with Sumner Global, which is critical for its operations.
• The company may not be able to raise sufficient capital to fund its operations, clinical trials, and debt repayment.
• The company's lead drug candidate, TLR-AD1, may not prove to be effective or safe in clinical trials.
• The company may face competition from other biopharmaceutical companies developing immunotherapies for brain cancer.
• The company may be exposed to product liability claims and may not have adequate insurance coverage.
• The company may not be successful in negotiating reimbursement for its products.
• The company may fail to comply with regulatory requirements, which could result in fines, injunctions, or suspension of approvals.
• The company's intellectual property rights may be challenged or infringed upon by third parties.

Future Outlook

The company plans to submit an IND application in 2024 and commercialize its products after successful clinical trials. They also intend to license their products to larger biopharmaceutical companies. The company expects to raise at least $5.0 million through December 31, 2024, to finance operations and debt payments.

Management Comments

• Management believes the existing shareholders and the prospective new investors will provide the additional cash needed to meet the Companys obligations as they become due and will allow the development of its business.
• Management has determined and our independent auditors have indicated in their report on our September 30, 2023 financial statements that there is substantial doubt about our ability to continue as a going concern.

Industry Context

The document highlights the significant demand for novel therapies to treat brain tumors, particularly glioblastoma, where survival rates have not improved in over 50 years. The company is positioning itself within the growing field of immunotherapy, which is being promoted by both the National Institutes of Health and the biopharmaceutical industry. The document also notes the competitive landscape with other companies developing immunotherapies and other cancer treatments.

Comparison to Industry Standards

• The document mentions Dendreon's Provenge as an example of a novel immunotherapy, but also notes the difficulties Dendreon faced in scaling up manufacturing for commercialization, which is a risk NovAccess also faces.
• The document notes that while many immune checkpoint inhibitors have been approved for cancer, they have been ineffective in Glioblastoma, highlighting the need for alternative approaches like NovAccess's personalized immunotherapy.
• The document acknowledges that very few personalized active immune therapies have been approved by the FDA, including one dendritic cell therapy and some CAR-T cell therapies, indicating the novelty and challenges of NovAccess's approach.
• The document notes that late-stage clinical trials for glioblastoma are expensive, typically requiring tens or hundreds of millions of dollars, and take years to reach their outcomes, which is a significant hurdle for NovAccess.
• The document mentions that the manufacturing of living cells requires specialized facilities, equipment and personnel which are entirely different than what is required for the manufacturing of chemical or biologic compounds, and that scaling up the manufacturing of living cell products to volume levels required for commercialization will require enormous amounts of these specialized facilities, equipment and personnel, especially where, as in the case of our TLR-AD1 product candidates, the product is personalized and must be made for each patient individually. This is a significant challenge for NovAccess.

Corporate Governance

Legal Proceedings

• The company is not involved in any legal proceedings.

Related Party Transactions

• The company has entered into loan agreements with board members and related entities.
• The company has a history of transactions with Innovest Global, Inc., including the acquisition of StemVax, LLC.
• The company has a history of transactions with TN3, LLC, including the redemption of preferred stock.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial challenges and the uncertainty of clinical trial outcomes.
• Employees and consultants may be impacted by the company's financial instability and potential need to curtail operations.
• Customers (potential patients) may benefit from the development of new therapies, but the timeline for commercialization is uncertain.
• Creditors face risk due to the company's outstanding debt and potential default.
• Suppliers may be impacted by the company's financial instability and potential need to curtail operations.

Next Steps

• The company plans to submit an IND application to the FDA in 2024.
• The company plans to complete the financing transaction with Sumner Global LLC.
• The company plans to conduct human clinical trials for TLR-AD1.
• The company plans to commercialize its products after successful clinical trials.
• The company plans to license its products to larger biopharmaceutical companies.

Key Dates

Keywords

immunotherapy, glioblastoma, brain tumor, biopharmaceutical, clinical trials, FDA, orphan drug designation, TLR-AD1, dendritic cell, cancer therapy, capital raise, convertible debt, financial risk, going concern